Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy [6]

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 808-809

  Durand, J P ^a   Gourmel, B ^a   Mir, Olivier ^a   Goldwasser, F ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CISPLATIN; DOXORUBICIN; DRUG METABOLITE; IFOSFAMIDE; METHYLPREDNISOLONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON;

ADULT; AUDITORY HALLUCINATION; BRAIN DISEASE; CALCANEUS; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL PROTOCOL; DIZZINESS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HUMAN; LETTER; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; SOMNOLENCE; VISUAL HALLUCINATION;

EID: 34047133864     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm104     Document Type: Letter

References (4)

1. Pelgrims J, De Vos F, Van den Brande J et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: Report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-294.
2. Brade WP, Herdrich K, Varini M. Ifosfamide pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12: 1-47.
3. Majumdar AK, McCrea JB, Panebianco DL et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003; 74: 150-156.
4. Shadle CR, Lee Y, Majumdar AK et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44: 215-223.